10 Notable FDA-Approved Rare Disease Treatments
Ten notable U.S. FDA-approved treatments for rare diseases are Soliris, Kalydeco, Spinraza, Brineura, Luxturna, Crysvita, Onpattro, Zokinvy, Imcivree, and Casgevy. This is a curated selection, not a ranking of clinical superiority. It highlights distinct regulatory milestones, a range of diseases and treatment modalities, and evidence documented in FDA records as of October 28, 2026.
Table of contents
- How the treatments were selected
- The ten treatments at a glance
- Why these treatments are notable
- Selected population expansions
- Scope and limitations
- Frequently asked questions
- Sources
How the treatments were selected
Each entry has an FDA orphan-designation record for a relevant use, an actual marketing approval for the selected rare-disease indication, and retrievable FDA labeling or product information. The list aims to show variety—from small molecules and biologics to RNA-based medicines and gene therapies. Each treatment is counted once: additional indications, formulations, strengths, and brands do not create separate entries.
FDA explains that orphan designation is separate from approval or licensure; it is not proof that a product has marketing approval. The list’s approval dates refer to the first FDA approval for the selected indication. Where a labeled population has since expanded, the table gives the current population and the entries note material changes from the original approval.
The ten treatments at a glance
| Treatment | Disease and current labeled population | Modality | First FDA approval for selected indication |
|---|---|---|---|
| Eculizumab (Soliris) | Paroxysmal nocturnal hemoglobinuria (PNH), to reduce hemolysis; pediatric PNH safety and effectiveness are not established | C5-blocking monoclonal antibody | March 16, 2007 |
| Ivacaftor (Kalydeco) | Cystic fibrosis (CF), age 1 month and older, with at least one ivacaftor-responsive CFTR mutation | Small-molecule CFTR potentiator | January 31, 2012 |
| Nusinersen (Spinraza) | Spinal muscular atrophy (SMA), pediatric and adult patients | SMN2-directed antisense oligonucleotide | December 23, 2016 |
| Cerliponase alfa (Brineura) | Pediatric CLN2 disease, to slow loss of ambulation; dosing not recommended below 37 weeks postmenstrual age or 2.5 kg | Intraventricular enzyme replacement | April 27, 2017 |
| Voretigene neparvovec-rzyl (Luxturna) | Confirmed biallelic RPE65 mutation-associated retinal dystrophy, with viable retinal cells; treatment below 12 months not recommended | Subretinal gene therapy | December 19, 2017 |
| Burosumab-twza (Crysvita) | X-linked hypophosphatemia (XLH), adults and children 6 months and older | FGF23-blocking monoclonal antibody | April 17, 2018 |
| Patisiran (Onpattro) | Hereditary transthyretin-mediated amyloidosis with polyneuropathy, adults | Transthyretin-directed siRNA | August 10, 2018 |
| Lonafarnib (Zokinvy) | Hutchinson-Gilford progeria syndrome (HGPS) mortality-risk reduction; age 12 months and older, BSA ≥0.39 m² | Farnesyltransferase inhibitor | November 20, 2020 |
| Setmelanotide (Imcivree) | Weight reduction and long-term maintenance from age 2 for qualifying genetically confirmed POMC, PCSK1, or LEPR deficiency | Peptide MC4 receptor agonist | November 25, 2020 |
| Exagamglogene autotemcel (Casgevy) | Sickle cell disease with recurrent vaso-occlusive crises, age 2 and older under the current label | Autologous CRISPR/Cas9 genome-edited cell therapy | December 8, 2023 |
Why these treatments are notable
1. Eculizumab (Soliris): complement inhibition for PNH
The selected milestone is Soliris’s 2007 approval for PNH, not its later approvals for other conditions. Its mechanism—blocking complement component C5—illustrates a targeted biologic approach to a rare blood disorder. The label carries a boxed warning for serious meningococcal infection and a restricted REMS program.
Orphan designation: PNH · Current FDA label
2. Ivacaftor (Kalydeco): mutation-directed CF treatment
Kalydeco’s 2012 approval was for a narrower group than its current label: patients 6 years and older with the G551D mutation. The current indication includes people from 1 month of age with at least one responsive CFTR mutation. This is a useful example of why historical approval populations and current labeled populations should be distinguished. The March 2026 label includes neuropsychiatric warnings, liver monitoring, and CYP3A interaction precautions.
Orphan designation: cystic fibrosis · Current FDA label
3. Nusinersen (Spinraza): antisense treatment for SMA
Approved in 2016, Spinraza represents an antisense approach directed at SMN2. Its label includes pediatric and adult patients and describes intrathecal administration. It also calls for monitoring related to platelet counts, coagulation, and renal toxicity.
Orphan designation: SMA · Current FDA label
4. Cerliponase alfa (Brineura): enzyme replacement in CLN2 disease
Brineura’s 2017 approval introduced an enzyme-replacement approach delivered into the ventricles of the brain for pediatric CLN2 disease. The labeled outcome is slowing loss of ambulation, not curing the disease. The July 24, 2024 expansion extended the original population of symptomatic children 3 years and older to include younger and asymptomatic pediatric patients. The label includes a boxed warning for anaphylaxis and contraindications involving the delivery device and infections.
Orphan designation: CLN2 disease · FDA label
5. Voretigene neparvovec-rzyl (Luxturna): gene therapy for inherited retinal dystrophy
Approved in 2017, Luxturna is a gene therapy for retinal dystrophy associated with confirmed biallelic RPE65 mutations. Eligibility also requires viable retinal cells. Its significance here is the distinct modality and highly specific genetic indication—not a claim of universal benefit. The FDA label describes ocular and surgical risks, including the potential for permanent visual-acuity decline.
Orphan designation: RPE65-associated retinal dystrophy · FDA product information and label
6. Burosumab-twza (Crysvita): targeting FGF23 in XLH
Crysvita was first approved for XLH in 2018. Its current label includes adults and children 6 months and older; the original pediatric age threshold was 1 year. Crysvita blocks FGF23. Contraindications include concurrent oral phosphate or active vitamin D analogues, normal or elevated phosphorus, and severe renal impairment or end-stage renal disease.
Orphan designation: XLH · Current FDA label
7. Patisiran (Onpattro): RNA interference for hereditary ATTR polyneuropathy
Approved in 2018, Onpattro uses small interfering RNA directed at transthyretin. The selected indication is specifically polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; it is not a blanket approval for all amyloidosis or cardiomyopathy. Its label includes infusion precautions, required premedication, and vitamin A supplementation.
Orphan designation: transthyretin-mediated amyloidosis · FDA label
8. Lonafarnib (Zokinvy): mortality-risk reduction in HGPS
Zokinvy’s 2020 approval is notable for its specified indication to reduce mortality risk in patients with HGPS. Its label also covers certain processing-deficient progeroid laminopathies under defined conditions. The population is restricted by age and body surface area, and the label includes QTc and drug-interaction restrictions.
Orphan designation: HGPS and progeroid laminopathies · FDA label
9. Setmelanotide (Imcivree): treatment for specific genetic obesity disorders
Imcivree was first approved in 2020 for patients 6 years and older. Its current indication covers patients from age 2 with qualifying, genetically confirmed POMC, PCSK1, or LEPR deficiency. This is not a general obesity indication: the label’s genetic criteria matter, and benign or likely benign variants do not qualify. The label also includes warnings concerning depression and suicidal ideation.
Orphan designation: POMC deficiency · Orphan designation: LEPR deficiency · Current FDA label
10. Exagamglogene autotemcel (Casgevy): CRISPR/Cas9 cell therapy
FDA approved Casgevy for sickle cell disease in 2023, identifying it as the first FDA-approved therapy using CRISPR/Cas9. The current label covers patients age 2 and older with recurrent vaso-occlusive crises; the original approval covered patients 12 years and older. Treatment involves cell collection and myeloablative conditioning. The label warns of risks including engraftment failure, delayed platelet engraftment, and unintended off-target genome editing.
Orphan designation: sickle cell disease · FDA approval announcement · Current FDA product information
Selected population expansions
These changes concern the selected indications, not additional treatments:
| Treatment | Original population → current population | Expansion date and FDA source |
|---|---|---|
| Kalydeco | Age 6 and older with G551D → age 1 month and older with an ivacaftor-responsive CFTR mutation | May 3, 2023: minimum-age expansion; mutation eligibility also broadened after initial approval |
| Brineura | Symptomatic children age 3 and older → pediatric patients, including younger and asymptomatic patients | July 24, 2024 |
| Crysvita | Age 1 year and older → age 6 months and older | September 27, 2019 |
| Imcivree | Age 6 and older → age 2 and older for qualifying genetic deficiencies | December 20, 2024 |
| Casgevy | Age 12 and older → age 2 and older for SCD with recurrent vaso-occlusive crises | July 1, 2026 |
The eligibility and dosing qualifications summarized above still apply.
Scope and limitations
This selection is not an exhaustive catalogue of orphan drugs, an efficacy comparison, or treatment advice. Dates identify first U.S. FDA approval for each selected rare-disease indication; populations reflect the current cited labels as checked on October 28, 2026. Approval does not establish suitability for a particular person, access, or affordability. Safety notes are selective, so consult the full prescribing information for complete restrictions and warnings.
The FDA’s orphan-designation database and Drugs@FDA provide different kinds of records. The Drugs@FDA data files describe application, product, and submission information; they do not substitute for indication-specific orphan-designation records. Drugs@FDA covers CDER-regulated products, not CBER-regulated cellular and gene therapies; consult the linked CBER product records for Luxturna and Casgevy rather than interpreting absence from Drugs@FDA as nonapproval.
For application-level research, explore QOPE’s FDA Approvals dataset for application and product numbers, sponsor, dosage form, strength, and selected submission fields. It does not provide orphan-designation records or complete submission history. Its selected submission is the highest numeric submission number per application, not necessarily the latest chronological action; its submission date derives from FDA’s submission-status date, with no separate action-date field. Verify indications and orphan status in the FDA sources linked above.
Frequently asked questions
Does orphan designation mean a drug is FDA-approved?
No. FDA describes designation and marketing approval as separate processes. Approval and the labeled population must be verified in the relevant FDA approval and labeling records.
Why does the table show both an approval date and a current population?
A product may receive approval for a rare-disease indication and later receive population expansions or other label changes. The date shown is for the first approval of the selected indication; the population is based on the current cited label.
Is this a ranking of the best rare disease drugs?
No. The entries are curated for regulatory milestones, diversity of diseases and modalities, and available official evidence. They do not compare efficacy across different diseases or trials.